|
Long-Term Outcomes after Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant Recipients |
03/29/2024 - 12:00pm to 1:00pm |
|
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy |
04/19/2024 - 12:00pm to 1:00pm |
|
Dialysate Sodium Lowering in Maintenance Hemodialysis |
05/17/2024 - 12:00pm to 1:00pm |
|
Arginine or Hypertonic Saline–Stimulated Copeptin to Diagnose AVP Deficiency |
05/31/2024 - 12:00pm to 1:00pm |
|
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes |
06/21/2024 - 12:00pm to 1:00pm |
|
Cosmic kidney disease: an integrated pan-omic, physiological and morphological study into spaceflight-induced renal dysfunction |
09/06/2024 - 12:00pm to 1:00pm |
|
Lower-Dosage Acute Peritoneal Dialysis versus Acute Intermittent Hemodialysis in Acute Kidney Injury |
09/20/2024 - 12:00pm to 1:00pm |
|
Epithelial Na1 Channel Activation after Bile Duct Ligation with Mineralocorticoid Receptor Blockade |
10/04/2024 - 12:00pm to 1:00pm |
|
Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study |
10/18/2024 - 12:00pm to 1:00pm |
|
Frailty, Multimorbidity, and Polypharmacy Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial |
11/08/2024 - 12:00pm to 1:00pm |
Facebook
X
LinkedIn
Forward